Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2026)

C4 Therapeutics has reported Income from Continuing Operations over the past 8 years, most recently at 25129000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 4.53% year-over-year to 25129000.0; the TTM value through Mar 2026 reached 103680000.0, changed 0.39%, while the annual FY2025 figure was 104994000.0, 0.31% changed from the prior year.
  • Income from Continuing Operations for Q1 2026 was 25129000.0 at C4 Therapeutics, down from 20365000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 17716000.0 in Q2 2024 and troughed at 37185000.0 in Q4 2022.
  • A 5-year average of 29144411.76 and a median of 28361000.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: crashed 137.48% in 2022 and later soared 50.68% in 2024.
  • Year by year, Income from Continuing Operations stood at 37185000.0 in 2022, then grew by 6.53% to 34757000.0 in 2023, then grew by 0.53% to 34573000.0 in 2024, then surged by 41.1% to 20365000.0 in 2025, then decreased by 23.39% to 25129000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for CCCC at 25129000.0 in Q1 2026, 20365000.0 in Q4 2025, and 32166000.0 in Q3 2025.